Clinical Trials Logo

Minimal Brain Dysfunction clinical trials

View clinical trials related to Minimal Brain Dysfunction.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03586115 Completed - Clinical trials for Hepatic Encephalopathy

Minimal Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasian

mHE-HHT
Start date: January 8, 2018
Phase:
Study type: Observational

HHT or Rendu-Osler-Weber disease is a genetic disease with an autosomal dominant inheritance pattern, characterized by widespread telangiectases that can involve several organs including the intestinal tract and the liver. Liver involvement by HHT is characterized by widespread diffuse liver vascular malformations that give origin to arteriovenous, arterioportal and portovenous shunts. The prevalence of hepatic involvement in HHT can reach 78%. Less commonly, patients may also develop porto-systemic encephalopathy (PSE). However, there are no studies on the possibility that patients with HHT might develop mHE, a highly plausible hypothesis considering the presence of diffuse macroscopic and microscopic porto-systemic shunt in this pathological condition.